SR-4835
Based on 19 publication(s) in Google Scholar
SR-4835 is a potent, highly selective and ATP competitive dual inhibitor of CDK12/CDK13 (CDK12: IC50=99 nM, Kd=98 nM; CDK13: Kd=4.9 nM). SR-4835 acts in synergy with DNA-damaging chemotherapy and PARP inhibitors and provokes triple-negative breast cancer (TNBC) cell death.
For research use only. We do not sell to patients.
- Purity: 99.47%
- CAS No.: 2387704-62-1
- Formula: C21H20Cl2N10O
- Molecular Weight:499.36
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Kinase Inhibitor Library
HY-L009
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Blood Cancer Compound Library
HY-L079
-
Targeted Diversity Library
HY-L099
-
Cancer Stem Cells Compound Library
HY-L135
-
Heterocyclic Compound Library
HY-L138
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Serine/Threonine Kinase Inhibitor Library
HY-L164
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
-
High-Efficiency Gene Editing Compound Library
HY-L244
Publications Citing Use of MedChemExpress (MCE) SR-4835
More- Mol Cell. 2024 Jun 6;84(11):2070-2086.e20. [Abstract]
- J Exp Clin Cancer Res. 2023 Aug 21;42(1):214. [Abstract]
- Cancer Lett. 2024 May 1:589:216820. [Abstract]
- Cell Rep. 2025 Nov 25;44(11):116495. [Abstract]
- EMBO Rep. 2025 Jun;26(11):2836-2854. [Abstract]
- Breast Cancer Res. 2023 May 5;25(1):51. [Abstract]
- Sci Rep. 2026 Apr 1.
- J Biol Chem. 2024 Jan;300(1):105501. [Abstract]
- Oncologie. 2023 Aug 8.
- Biochem Biophys Res Commun. 2024 Aug 28:735:150608. [Abstract]
- Res Sq. 2026 Apr 16.
- bioRxiv. 2026 Feb 20.
- Res Sq. 2025 Dec 18.
- bioRxiv. 2025 Nov 20.
- Research Square Preprint. 2024 Jan 31.
- bioRxiv. 2023 Jul 17.
- University of Gothenburg. 2023 Jun 27.
- bioRxiv. 2023 May 31.
- Universidade de Lisboa. 2021 Dec 21.
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
Bio/Physico-chemical Assay
-
Bio/Physico-chemical Assay
Biological Activity
|
CDK12 99 nM (IC50) |
CDK12 98 nM (Kd) |
CDK13 4.9 nM (Kd) |
SR-4835 (90 nM; 0.5-48 hours) suppresses ATM and RAD51 protein levels[1].
?
SR-4835 inhibits CDK12/CDK13 which triggers intronic polyadenylation site cleavage and suppresses the expression of core DNA damage response proteins[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MDA-MB-231 cells
-
Concentration:90 nM
-
Incubation Time:0.5, 6, 24, 48 hours
-
Result:Suppressed ATM and RAD51 protein levels.
Chemical Information
-
CAS No. 2387704-62-1
-
Appearance Solid
-
Molecular Weight 499.36
-
Formula C21H20Cl2N10O
-
Color Off-white to light brown
-
SMILES
CN1N=CC(N2C3=NC(N4CCOCC4)=NC(NCC5=NC6=C(N5)C=C(Cl)C(Cl)=C6)=C3N=C2)=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (19)
-
Journal Impact Factor
-
Most Recent
-
Mol Cell
The MYCN oncoprotein is an RNA-binding accessory factor of the nuclear exosome targeting complex. [Abstract]2024 Jun 6;84(11):2070-2086.e20. PMID: 38703770 -
J Exp Clin Cancer Res
MYC up-regulation confers vulnerability to dual inhibition of CDK12 and CDK13 in high-risk Group 3 medulloblastoma. [Abstract]2023 Aug 21;42(1):214. PMID: 37599362 -
Cancer Lett
CDK inhibition results in pharmacologic BRCAness increasing sensitivity to olaparib in BRCA1-WT and olaparib resistant in Triple Negative Breast Cancer. [Abstract]2024 May 1:589:216820. PMID: 38574883 -
Cell Rep
CDK12 inhibition reveals melanoma dependence on the RUNX1/CBFβ complex for genomic stability. [Abstract]2025 Nov 25;44(11):116495. PMID: 41176765 -
EMBO Rep
DDB1 engagement defines the selectivity of S656 analogs for cyclin K degradation over CDK inhibition. [Abstract]2025 Jun;26(11):2836-2854. PMID: 40295725
SR-4835 purchased from MedChemExpress. Usage Cited in: EMBO Rep. 2025 Jun;26(11):2836-2854. [Abstract]
Inhibitory profile of S656, CR8, SR4835, HQ461, NCT02, THZ531 and SNS-032 compounds across 40 primary AML specimens in dose response assays. IC50 values were determined after 6 days of incubation and normalized to DMSO control.
-
Breast Cancer Res
Systematic screening identifies ABCG2 as critical factor underlying synergy of kinase inhibitors with transcriptional CDK inhibitors. [Abstract]2023 May 5;25(1):51. PMID: 37147730
SR-4835 purchased from MedChemExpress. Usage Cited in: Breast Cancer Res. 2023 May 5;25(1):51. [Abstract]
Proliferative response upon treatment with dose range of lapatinib in combination with transcriptional CDK inhibitor SR4835 (0.01 and 0.0316 µM) in Hs578T.
SR-4835 purchased from MedChemExpress. Usage Cited in: Breast Cancer Res. 2023 May 5;25(1):51. [Abstract]
Proliferative responses of dose ranges of transcriptional CDK inhibitors THZ531, THZ1, CDKI-73, PHA-767491, SR4835 and flavopiridol, alone, or in combination with KO143 (1 µM) or lapatinib (1 µM).
-
-
J Biol Chem
The reversible inhibitor SR-4835 binds Cdk12/Cyclin K in a non-canonical G-loop conformation. [Abstract]2024 Jan;300(1):105501. PMID: 38016516
SR-4835 purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2024 Jan;300(1):105501. [Abstract]
dose-response curves for the inhibition of Cdk12/CycK and Cdk13/CycK by SR-4835. Radioactive kinase activity assays were performed for a concentration series of SR-4835 in presence of 0.2 μM indicated kinase and 0.2 mM [32P]-γ-ATP. Assays were started by addition of 100 μM pS7-CTD[3] substrate and incubated for 60 min. Measurements were performed in triplicates.
SR-4835 purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2024 Jan;300(1):105501. [Abstract]
SR-4835 was tested at 0, 0.1, 1, 10, and 100 μM concentration against various CMGC kinases.
-
-
Biochem Biophys Res Commun
Interaction of CDK12 with NXF1 is a new node for the linking mechanism between transcription and transportation of mRNA. [Abstract]2024 Aug 28:735:150608. PMID: 39270556 -
-
-
-
-
-
-
-
-
Solvent & Solubility
DMSO : 25 mg/mL (50.06 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2 mg/mL (4.01 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 20% HP-β-CD in Saline
Solubility: 5 mg/mL (10.01 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.0026 mL | 10.0128 mL | 20.0256 mL | 50.0641 mL |
| 5 mM | 0.4005 mL | 2.0026 mL | 4.0051 mL | 10.0128 mL | |
| 10 mM | 0.2003 mL | 1.0013 mL | 2.0026 mL | 5.0064 mL | |
| 15 mM | 0.1335 mL | 0.6675 mL | 1.3350 mL | 3.3376 mL | |
| 20 mM | 0.1001 mL | 0.5006 mL | 1.0013 mL | 2.5032 mL | |
| 25 mM | 0.0801 mL | 0.4005 mL | 0.8010 mL | 2.0026 mL | |
| 30 mM | 0.0668 mL | 0.3338 mL | 0.6675 mL | 1.6688 mL | |
| 40 mM | 0.0501 mL | 0.2503 mL | 0.5006 mL | 1.2516 mL | |
| 50 mM | 0.0401 mL | 0.2003 mL | 0.4005 mL | 1.0013 mL |
Powered by Bioz